Showing results (1-10 of 65) with videos related to
Sort By:
Pageof 7
Annual Review of Medicine|September 20, 2023
New Biological Therapies for Multiple MyelomaAlfred L GarfallHematology. American Society of Hematology. Education Program|December 4, 2016
Cellular and vaccine immunotherapy for multiple myelomaAlfred L Garfall, Edward A StadtmauerBlood Cancer Discovery|September 28, 2023
Understanding Infection Risk with Anti-BCMA Bispecific AntibodiesAlfred L Garfall, Edward A StadtmauerHematology. American Society of Hematology. Education Program|December 9, 2023
Options at the time of relapse after anti-BCMA therapyBeatrice Razzo, Alfred L Garfall, Adam D CohenCancer Journal (Sudbury, Mass.)|February 4, 2016
The Promise of Chimeric Antigen Receptor Engineered T Cells in the Treatment of Hematologic MalignanciesSarah J Nagle, Alfred L Garfall, Edward A StadtmauerDiscovery Medicine|January 14, 2014
Immunotherapy with chimeric antigen receptors for multiple myelomaAlfred L Garfall, Joseph A Fraietta, Marcela V MausAmerican Journal of Hematology|February 8, 2019
Chimeric antigen receptor T cell immunotherapy for multiple myeloma: A review of current data and potential clinical applicationsSandra P Susanibar Adaniya, Adam D Cohen, Alfred L GarfallCancer Research|August 3, 2007
Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancerKatherine M Bell-McGuinn, Alfred L Garfall, Matthew Bogyo, et al.Muscle & Nerve|July 30, 2026
Neuralgic Amyotrophy Following B-Cell Maturation Antigen-Directed CAR-T TherapyEduardo J Pérez-Torres, Daria V Madeeva, Adam D Cohen, et al.Blood Cancer Discovery|September 25, 2024
T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma: Optimal Dosing Schedule and Duration of TreatmentNiels W C J van de Donk, Leo Rasche, Surbhi Sidana, et al.Pageof 7